Merz Therapeutics, part of the Merz Group and a leader in neurotoxin therapies, today announced that Health Canada has approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity…
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading biopharmaceutical provider in China, has announced the initiation of a Phase III clinical trial for its bivalent vaccine candidate,…
QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine, announced the appointment of John R. Chiminski and R. Scott…
CVS Health Corporation (NYSE: CVS) has announced the results of its previously disclosed cash tender offer (the “Any and All Tender Offer”) for its 4.100% Senior Notes due 2025 (the…
Newron Pharmaceuticals S.p.A. has entered into a license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., to develop, manufacture, and commercialize Newron’s innovative glutamate modulator, evenamide,…
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol, announced today that the primary endpoint…
Syncell, a leader in advanced subcellular protein purification and spatial proteomics analysis, has successfully closed a $15 million Series A funding round, bringing its total funding to $30 million. The…
MiSalud Health, a prominent digital health platform providing affordable, same-day bilingual (Spanish/English) telehealth consultations in both the United States and Mexico, has named co-founder Bismarck Lepe as the company’s new…
MiSalud Health, a prominent digital health platform offering affordable, same-day bilingual telehealth consultations (Spanish/English) in the U.S. and Mexico, has announced the appointment of co-founder Bismarck Lepe as CEO. Lepe…
Celltrion announced today that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is now approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also…
Genentech, a member of the Roche Group, today announced five-year follow-up data from the pivotal Phase III POLARIX study. The study evaluated Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),…
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into a strategic partnership to investigate the potential of IPH6501, Innate’s anti-CD20…